netFormulary NHS
Herefordshire & Worcestershire
Medicines and Prescribing Committee
 Search
 Formulary Chapter 2: Cardiovascular system - Full Chapter
02.08.02  Expand sub section  Oral anticoagulants
Warfarin Sodium
View adult BNF View SPC online View childrens BNF
Formulary
Green
 
Link  COVID 19 Interim Publication: Safe Switching of Warfarin to DOACs - Clinical Guidance
Link  MHRA Drug Dafety Update (Jul 16): Warfarin: reports of calciphylaxis
 
Edoxaban
View adult BNF View SPC online
Formulary
Green

Edoxaban should be prescribed as first line DOAC in the treatment of non-valvular AF.

 
Link  NICE TA354 Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Link  NICE TA355 Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
 
Apixaban
View adult BNF View SPC online View childrens BNF
Formulary
Green
 
Link  NICE TA245 Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Link  NICE TA275 Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation
Link  NICE TA341 Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
 
Dabigatran
View adult BNF View SPC online View childrens BNF
Formulary
Green
 
Link  NICE TA157 Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults September 2008
Link  NICE TA249 Atrial fibrilation - dabigatran etexilate March 2012
Link  NICE TA327 - an option for treatment and for secondary prevention of recurrent DVT & PE.
 
Rivaroxaban
View adult BNF View SPC online View childrens BNF
Formulary
Green
 
Link  MHRA - Drug Safety Update (Oct 2018): Rivaroxaban (Xarelto▼) after transcatheter aortic valve replacement: increase in all-cause mortality, thromboembolic and bleeding events in a clinical trial
Link  MHRA Drug Safety Update (Jul 19): Rivaroxaban (Xarelto▼): Reminder that 15 mg and 20 mg tablets should be taken with food
Link  NICE TA 607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
Link  NICE TA170 Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults April 2009
Link  NICE TA256 Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrilation. May 2012
Link  NICE TA261 Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Link  NICE TA287 Pulmonary embolism and recurrent venous thromboembolism
Link  NICE TA335 Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
 
Phenindione
View adult BNF View SPC online View childrens BNF
Formulary
Amber

Only when warfarin or DOAC not tolerated / clinically appropriate

 
 
Acenocoumarol
View adult BNF View SPC online View childrens BNF
Formulary
Amber

Only when warfarin, phenindione or DOAC not tolerated / clinically appropriate

 
 
02.08.02  Expand sub section  Stroke prevention in AF
02.08.02  Expand sub section  Atrial Fibrillation
02.08.02  Expand sub section  VTE treatment
02.08.02  Expand sub section  VTE prophylaxis in hip/knee surgery to top
02.08.02  Expand sub section  VTE Prophylaxis
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Secondary care only, not to be prescribed in primary care.   

Amber 2

Specialist initiation with shared care guidance Medicines which should be initiated in secondary care by the specialist with follow-on prescription and monitoring according to a specific Shared Care (SC) Guideline. Prescribing may be continued in primary care in line with a shared care guideline   

Amber with Shared Care

Specialist initiation with shared care guidance Medicines which should be initiated in secondary care by the specialist with follow-on prescription and monitoring according to a specific Shared Care (SC) Guideline. Prescribing may be continued in primary care in line with a shared care guideline   

Amber

Considered suitable for primary care prescribing following specialist initiation/recommendation.  

Green

Considered appropriate for prescribing in both secondary and primary care. Suitable for initiation in primary care.   

netFormulary